Open house discount agreements Botulinum toxin type A, finished medicinal product designation Dysport(R)/Dysline(R), ATC M03AX21
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Botulinumtoxin Typ A, Fertigarzneimittelbezeichnung Dysport(R)/Dysline(R), ATC M03AX21
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume provided; actual sales may be low
Contracts automatically terminate if a competing nationwide or regional discount contract takes effect
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2028
- Non-exclusive discount agreements for Botulinum toxin type A, finished medicinal product designation Dysport(R)/Dysline(R), ATC M03AX21
- Contracting with all interested pharmaceutical companies under identical non-negotiable terms
Show full summary
Open-house model for non-exclusive discount agreements on Botulinum toxin type A (Dysport/Dysline) with AOK Bayern. No competitive selection; all eligible pharmaceutical companies can join. Contracts run from July 1, 2026 to June 30, 2028. Submission of signed contract and declaration of reliability required.
Risks
No estimated value or volume provided; actual sales may be low
Contracts automatically terminate if a competing nationwide or regional discount contract takes effect
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company
Administrative
- Submit signed contract, annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability
- Documents in German or with German translation
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house discount agreements Botulinum toxin type A, finished medicinal product designation Dysport(R)/Dysline(R), ATC M03AX21
Non-exclusive framework agreement for discount on Botulinum toxin type A (Dysport/Dysline) with AOK Bayern. All eligible pharmaceutical companies may join. Contract duration 2 years.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Botulinumtoxin Typ A, Fertigarzneimittelbezeichnung Dysport(R)/Dysline(R), ATC M03AX21
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 17 May 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 338689-2026
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume provided; actual sales may be low
Contracts automatically terminate if a competing nationwide or regional discount contract takes effect
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications